CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation

Front Immunol. 2023 Feb 1:14:1110482. doi: 10.3389/fimmu.2023.1110482. eCollection 2023.

Abstract

In engineered T cells the CAR is co-expressed along with the physiological TCR/CD3 complex, both utilizing the same downstream signaling machinery for T cell activation. It is unresolved whether CAR-mediated T cell activation depends on the presence of the TCR and whether CAR and TCR mutually cross-activate upon engaging their respective antigen. Here we demonstrate that the CD3ζ CAR level was independent of the TCR associated CD3ζ and could not replace CD3ζ to rescue the TCR complex in CD3ζ KO T cells. Upon activation, the CAR did not induce phosphorylation of TCR associated CD3ζ and, vice versa, TCR activation did not induce CAR CD3ζ phosphorylation. Consequently, CAR and TCR did not cross-signal to trigger T cell effector functions. On the membrane level, TCR and CAR formed separate synapses upon antigen engagement as revealed by total internal reflection fluorescence (TIRF) and fast AiryScan microscopy. Upon engaging their respective antigen, however, CAR and TCR could co-operate in triggering effector functions through combinatorial signaling allowing logic "AND" gating in target recognition. Data also imply that tonic TCR signaling can support CAR-mediated T cell activation emphasizing the potential relevance of the endogenous TCR for maintaining T cell capacities in the long-term.

Keywords: CAR; TCR; adoptive cell therapy; immunotherapy; synapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD3 Complex
  • Receptor-CD3 Complex, Antigen, T-Cell / metabolism
  • Receptors, Antigen, T-Cell*
  • Receptors, Chimeric Antigen / immunology
  • Signal Transduction
  • T-Lymphocytes*

Substances

  • CD3 Complex
  • Receptor-CD3 Complex, Antigen, T-Cell
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen

Grants and funding

This research was funded by the German Federal Ministry of Education and Research through the CD20 CAR-TIME consortium within the funding program “Innovations for Individualized Medicine” (Fkz 01EK1507A-C), the European Union through the EN-ACTI2NG consortium (H2020-MSCA-ITN-2016 GA HYPERLINK “tel:721358” 721358), the Center of Molecular Medicine Cologne (CMMC), and the National Research, Development and Innovation Office, Hungary (OTKA K143771, FK132773 and GINOP- HYPERLINK “tel:23215201600044” 2.3.2-15-2016-00044).